Colon Pharmaceuticals announced that its holding subsidiary Colunbotai has established a strategic partnership with Crescent Biopharma to jointly develop and commercialize cancer treatments. The collaboration involves Collombott's SKB105 and Crescent's CR-001, both drugs used to treat solid tumors. Columbite grants Crescent exclusive rights in markets other than Greater China, and Crescent grants exclusive rights to Columbertec in the Greater China region. Cooperation includes the evaluation of monotherapy and combination therapy. Colombotech will collect an initial payment of $80 million, as well as milestone payments of up to $1.25 billion and royalties based on sales. Crescent will collect a $20 million down payment, as well as up to $30 million in milestone payments and royalties based on sales.

Zhitongcaijing · 2d ago
Colon Pharmaceuticals announced that its holding subsidiary Colunbotai has established a strategic partnership with Crescent Biopharma to jointly develop and commercialize cancer treatments. The collaboration involves Collombott's SKB105 and Crescent's CR-001, both drugs used to treat solid tumors. Columbite grants Crescent exclusive rights in markets other than Greater China, and Crescent grants exclusive rights to Columbertec in the Greater China region. Cooperation includes the evaluation of monotherapy and combination therapy. Colombotech will collect an initial payment of $80 million, as well as milestone payments of up to $1.25 billion and royalties based on sales. Crescent will collect a $20 million down payment, as well as up to $30 million in milestone payments and royalties based on sales.